ASX:MSB

Email Alerts for:
ASX:MSB

Materials lift local bourse as travel stocks head south on COVID-19 resurgence: ASX closes 0.03% higher

22 Jun 2020 - The local share market opened lower this morning, picked up pace at lunchtime and then pared gains in late trade to end the session ever so slightly higher by 0.03 pe…

Banks reverse early falls and gold stocks push higher: ASX lifts 0.1% at noon

22 Jun 2020 - The ASX dropped 49 points at the open but has pared losses as the major banks reverse early falls, and gold stocks push higher. The top 200 is now 0.1 per cent higher…

Mesoblast's REMESTEMCEL-L "significantly improved outcomes" in patients with inflammatory lung disease and COVID-19

01 Jun 2020 - Mesoblast (ASX:MSB) says its lead mesenchymal stem cell (MSC) product candidate remestemce-L treatment showed significantly improved outcomes for patients with chroni…

Blackmores (ASX:BKL) completes its $92m institutional placement: Aus shares close 1.32% higher

28 May 2020 - The Australian share market rose at the open and continued to rally, closing 1.3 per cent up at the end of today’s trade. 93% of businesses accessed support measures …

Mesoblast (ASX:MSB) reports a net loss US$45.3 million for nine months

28 May 2020 - Mesoblast (ASX:MSB), the company that develops cellular medicines for inflammatory diseases, has reported a net loss of $US45.3 million in the nine months to the end …

Annual wage growth slow pre-coronavirus restrictions: The ASX is tracking 0.9% lower

13 May 2020 - The ASX dropped at the open as investors evaluate the risk of opening up the economy. It is now tracking almost 0.9 per cent lower at noon. Pilbara Minerals (ASX:PLS)…

Mesoblast (ASX:MSB) dose first COVID-19 patients in Phase 2/3 trial

06 May 2020 - Mesoblast (ASX:MSB) today announced that the first patients have been dosed in the 300-patient randomized placebo-controlled Phase 2/3 trial in the United States of M…

Mesoblast (ASX:MSB) commences remestemcel-L trial

30 Apr 2020 - Mesoblast (ASX:MSB) has commenced enrollment for its controlled trial of the remestemcel-L treatment.

Market closes on a 4-week high: ASX closed 3.5% higher

09 Apr 2020 - The ASX saw a rally in late afternoon trade closing on a 4 week high at 3.5% higher. Perenti Global (ASX:PRN) shares advanced over 27% and shares in Commonwealth Bank…

Mesoblast (ASX:MSB) see trials for COVID-19 lung distress

09 Apr 2020 - Mesoblast (ASX:MSB) today announced that its stem cell product candidate remestemcel-L will be formally evaluated in a randomized, placebo-controlled trial in patient…

ASX rallies: Aus shares close 3.1 per cent higher

10 Mar 2020 - The Australian share market closed 3.1 per cent higher at the end of today’s session. Investors were buying up Energy stocks today with Viva Energy Group (ASX:VEA) le…

Mesoblast (ASX:MSB) to evaluate stem cell therapy for COVID-19: Aus drop 0.4% at noon

10 Mar 2020 - The Australian share market opened lower again this morning dropping 0.4 per cent by noon. Overnight, the Dow entered into an emergency 15 minute trading halt to prev…

Why the Aussie share market has more upside

20 Jan 2020 - Fairmont Equities Managing Director Michael Gable takes a technical look at why the Aussie share market has more upside

Mesoblast (ASX:MSB) presents at Biotech showcase in San Francisco

15 Jan 2020 - Mesoblast (ASX:MSB) presents at Biotech showcase in San Francisco.

Mesoblast (ASX:MSB) files positive clinical efficacy and safety data

02 Jan 2020 - Cellular medicinal provider, Mesoblast (ASX:MSB, NASDAQ:MESO) has lodged positive clinical efficacy and safety data with the US FDA for its lead product candidate, re…

Global stocks fall on economic growth worries: ASX closes 2.2% lower

03 Oct 2019 - It has been a disappointing day of trade for the ASX. After opening in the black the local bourse failed to gain momentum to close 2.2% lower. Ooh!Media (ASX:OML) dro…

Mesoblast completes $75 million capital raising

03 Oct 2019 - Leader in cellular medicines for inflammatory diseases, Mesoblast (ASX:MSB) has successfully completed a $75 million capital raising.

Mesoblast see strong commercialisation revenues for the quarter

30 Jul 2019 - Mesoblast (ASX:MSB) today reported its operational highlights for their fourth quarter showing growth in revenues achieved by their Japanese partner in the treatment …

Property prices fall more than expected: Aus shares bounce back, 0.4% higher at noon

18 Jun 2019 - The local share market bounces back from yesterday’s fall, rising 0.4% at noon with most sectors charging higher. Property prices fall 3% in March Qtr, more than 2.5%…

Mesoblast expands JCR partnership to brain disease in newborns

11 Jun 2019 - Mesoblast (ASX:MSB) has today announced it has expanded its partnership with JCR Pharmaceuticals in Japan (to the use of mesenchymal stem cells (MSCs)) for the treatm…

Mesoblast enters MoU for US clinical trial for Revascor

27 Mar 2019 - Mesoblast (ASX:MSB) today announced that the International Center for Health Outcomes and Innovation Research have entered into a MoU for a clinical trial using Mesob…

Mesoblast draws down $15m of capital to accelerate product commercialisation programs

14 Jan 2019 - Mesoblast (ASX:MSB) has today announced it has drawn down (a further) $15 million from its US$75 million four-year credit facility with Hercules Capital.

Healius shares dip after rejecting takeover offer: ASX is 1.5% higher at noon

07 Jan 2019 - The ASX has continued to rise throughout this morning after the US posted solid gains on Friday after a boost from impressive employment data from all jobs except far…

Christmas holiday week ends on the up: ASX closes 1.02% higher

28 Dec 2018 - It has been a positive day of trade for the Australian share market as the market closed in positive territory. Most of this week's gains came on Thursday. The big fo…

Mesoblast pipeline growth in regenerative medicine industry

28 Dec 2018 - Mesoblast (ASX:MSB) today released their corporate review showing how the company will enter 2019 with the most mature cell therapy product pipeline and technology pl…